| Computerized Dynamic Posturography | MMP258.12 · Effective Sep 1, 2026 | 2 | Original policy ↗ |
| Computerized Dynamic Posturography – Commercial and Individual Exchange Medical Policy | 2026T0208DD · Commercial | 2 | Original policy ↗ |
| Consultation Services Policy, Professional | 2026R0129A · Effective Jun 1, 2019 · Commercial | 15 | Original policy ↗ |
| Continuous Glucose Monitoring and Insulin Delivery for Managing Diabetes | 2026T0347XX · Effective Aug 1, 2026 · Commercial | 22 | Original policy ↗ |
| Contrast and Radiopharmaceutical Materials Policy, Professional | Commercial | 40 | Original policy ↗ |
| Corneal Topography | MMP062.16 · Effective Oct 1, 2026 | 2 | Original policy ↗ |
| Cosentyx® (Secukinumab) | 2026D0132E · Effective Jun 1, 2026 · Commercial | 1 | Original policy ↗ |
| Cosmetic and Reconstructive Procedures | MP.007.33 · Effective Jun 1, 2026 · Commercial | 104 | Original policy ↗ |
| Cosmetic and Reconstructive Procedures | MMP022.16 · Effective Sep 1, 2026 | 100 | Original policy ↗ |
| Crysvita® (Burosumab-Twza) | 2026D0071O · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Deep Brain and Cortical Stimulation – Commercial and Individual Exchange Medical Policy | 2026T0321LL · Commercial | 18 | Original policy ↗ |
| Deep Brain and Responsive Cortical Stimulation | MMP395.02 · Effective Sep 1, 2026 | 14 | Original policy ↗ |
| Denosumab | 2026D0068U · Effective Oct 1, 2026 · Commercial | 11 | Original policy ↗ |
| Device, Implant, and Skin Substitute Policy, Facility | Commercial | 19 | Original policy ↗ |
| Diabetes Mellitus Testing Policy, Professional and Facility | 2026R8000A · Effective Aug 26, 2026 · Commercial | 2 | Original policy ↗ |
| Diagnosis Code Requirement Policy, Professional and Facility | 2026R5034B · Commercial | — | Original policy ↗ |
| Diagnostic Dynamic Spinal Visualization and Vertebral Motion Analysis | 2026T0633J · Effective Oct 1, 2026 · Commercial | 3 | Original policy ↗ |
| Diagnostic Testing for Inflammatory Bowel Disease Policy, Professional and Facility | 2026R8017A · Effective Dec 1, 2025 · Commercial | 14 | Original policy ↗ |
| Diagnostic Testing for Influenza Policy, Professional and Facility | 2026R8003A · Effective Aug 26, 2026 · Commercial | 8 | Original policy ↗ |
| Discogenic Pain Treatment | 2026T0105EE · Effective Jan 1, 2026 · Commercial | 9 | Original policy ↗ |
| Drug Testing Policy, Professional | Commercial | 35 | Original policy ↗ |
| Durable Medical Equipment (DME), Prosthetics, Orthotics (Non-Foot Orthotics), Nutritional Therapy, and Medical Supplies Grid | MMP028.23 · Effective Oct 1, 2025 | 178 | Original policy ↗ |
| Durable Medical Equipment, Orthotics and Prosthetics Policy, Professional | 2026R0109C · Commercial | 81 | Original policy ↗ |
| Durable Medical Equipment, Orthotics, Medical Supplies, and Repairs/Replacements – Commercial and Individual Exchange Medical Policy | MP.009.35 · Commercial | 7 | Original policy ↗ |
| Ear, Nose, and Throat Procedures | MMP060.18 · Effective Oct 1, 2026 | 27 | Original policy ↗ |
| Edaravone | 2026D0062M · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Elective Inpatient Services | MP.19.10 · Effective Jan 1, 2026 · Commercial | — | Original policy ↗ |
| Electric Tumor Treatment Field Therapy | 2026T0582S · Effective Sep 1, 2026 · Commercial | 3 | Original policy ↗ |
| Electrical and Ultrasonic Bone Growth Stimulators | 2026T0561X · Effective Feb 1, 2026 · Commercial | 7 | Original policy ↗ |
| Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation | 2026T0126VV · Effective Oct 1, 2026 · Commercial | 44 | Original policy ↗ |
| Electrical Stimulators | MMP090.18 · Effective Sep 1, 2026 | 8 | Original policy ↗ |
| Electromagnetic Therapy for Wounds | 2026T0527W · Effective Mar 1, 2026 · Commercial | 3 | Original policy ↗ |
| Elevidys® (Delandistrogene Moxeparvovec-Rokl) | 2026D0126G · Effective Mar 1, 2026 · Commercial | 1 | Original policy ↗ |
| Emergency Department (ED) Facility Evaluation and Management (E&M) Coding Policy | Commercial | 6 | Original policy ↗ |
| Encelto® (Revakinagene Taroretcel-Lwey) | 2026D0137C · Effective Aug 1, 2026 · Commercial | 1 | Original policy ↗ |
| Enjaymo® (Sutimlimab-Jome) – Commercial and Individual Exchange Medical Benefit Drug Policy | 2026D0100G · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Enteral Nutrition (Oral and Tube Feeding) | MP.027.14 · Effective May 1, 2026 · Commercial | 20 | Original policy ↗ |
| Entyvio® (Vedolizumab) | 2026D0053Q · Effective Aug 1, 2026 · Commercial | 1 | Original policy ↗ |
| Enzyme Testing for Acute Pancreatitis Policy, Professional and Facility | 2026R8018A · Effective Aug 26, 2026 · Commercial | 7 | Original policy ↗ |
| Epidural Steroid Injections for Spinal Pain | 2026T0616O · Effective Sep 10, 2026 · Commercial | 9 | Original policy ↗ |
| Epiduroscopy, Epidural Lysis of Adhesions, and Discography | 2026T0206DD · Effective Jan 1, 2026 · Commercial | 8 | Original policy ↗ |
| Epithelial Cell Cytology Policy, Professional and Facility | 2026R8009A · Effective Aug 26, 2026 · Commercial | 5 | Original policy ↗ |
| Erythropoiesis-Stimulating Agents | 2026D0028Y · Effective Apr 1, 2026 · Commercial | 8 | Original policy ↗ |
| Evaluation and Management (E/M) Policy, Professional | Commercial | 53 | Original policy ↗ |
| Evenity® (Romosozumab-Aqqg) | 2025D0080L · Effective Dec 1, 2025 · Commercial | 1 | Original policy ↗ |
| Evkeeza® (Evinacumab-Dgnb) | 2026D0104J · Effective Apr 1, 2026 · Commercial | 1 | Original policy ↗ |
| Exondys 51® (Eteplirsen) | 2026D0058O · Effective May 1, 2026 · Commercial | 1 | Original policy ↗ |
| Experimental Procedures and Items, Investigational Devices, and Clinical Trials | MMP393.06 · Effective Oct 1, 2026 | — | Original policy ↗ |
| Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications | 2026T0269MM · Effective Oct 1, 2026 · Commercial | 5 | Original policy ↗ |
| Facet Joint and Medial Branch Block Injections for Spinal Pain | 2026T0004WW · Effective Sep 10, 2026 · Commercial | 12 | Original policy ↗ |
